TNFSF13B
Tumor necrosis factor ligand superfamily member 13B
As of the edition of 20 October 2026, TNFSF13B (tumor necrosis factor ligand superfamily member 13B, UniProt Q9Y275) has 7 drugs tested at it and 12 companies on the list, 2 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9Y275
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 12
- Disease areas
- Immune system; Skin and connective tissue; Bones, joints and muscles; Pregnancy and women's health; Urinary and reproductive; Nervous system; Cancer; Eye
- Registered trials of its drugs
- 192
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 3 |
| Stopped | 2 |
| Total | 7 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Belimumab | Marketed | Phase 4 | Ended 2023 |
| Telitacicept | Active | Phase 4 | none listed |
| Tabalumab | Stopped | Phase 3 | none listed |
| Atacicept | Marketed | Phase 3 | Ends 2038 |
| Blisibimod | Stopped | Phase 3 | none listed |
| Tibulizumab | Active | Phase 3 | none listed |
| Rozibafusp alfa | Active | Phase 2 | none listed |
7 of 7 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 2 |
| Engaged | 7 |
| Undetermined | 1 |
| Total on the list | 12 |
| Company | Route |
|---|---|
| GSK | Route B |
| Vera Therapeutics | Route B |
| Anthera Pharmaceuticals | Route A |
The other 9 companies at TNFSF13B
In the product12 companies in all; 9 are not named here, and no score is.
See the 12 companies at TNFSF13B, ranked, with the facts behind eachRequest access. Nothing is shown until you do.